Regeneron Pharmaceuticals (REGN)

• Market cap: $65.5B
• 1 day: 5.25%
• 5 days: 1.33%
• 1 month: -5.59%
• 3 months: -12.34%
• 6 months: -35.11%
• Year to date: -16.28%
• 1 year: -32.77%
• 5 years: 13.86%
• 10 years: 30.89%
• Sector: Healthcare
• Industry: Biotechnology

About: Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 15,106

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

2% more call options, than puts

Call options by funds: $1.19B | Put options by funds: $1.17B

0.93% more ownership

Funds ownership: 85.11% [Q3] → 86.05% (+0.93%) [Q4]

2% less repeat investments, than reductions

Existing positions increased: 473 | Existing positions reduced: 482

6% less funds holding

Funds holding: 1,365 [Q3] → 1,289 (-76) [Q4]

22% less first-time investments, than exits

New positions opened: 164 | Existing positions closed: 210

31% less capital invested

Capital invested by funds: $95.9B [Q3] → $66.3B (-$29.6B) [Q4]

39% less funds holding in top 10

Funds holding in top 10: 23 [Q3] → 14 (-9) [Q4]

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $547 9% downside
• Avg. target: $778 30% upside
• High target: $1,000 67% upside

12 analyst ratings

• positive: 9 75%
• neutral: 2 17%
• negative: 1 8%

Truist Securities Srikripa Devarakonda 32% 1-year accuracy 11 / 34 met price target	57% upside $940	Buy Maintained	30 Apr 2025
Goldman Sachs Salveen Richter 20% 1-year accuracy 4 / 20 met price target	34% upside $804	Buy Maintained	30 Apr 2025
RBC Capital Brian Abrahams 19% 1-year accuracy 13 / 70 met price target	57% upside $943	Outperform Maintained	30 Apr 2025
Wells Fargo Mohit Bansal 46% 1-year accuracy 12 / 26 met price target	17% upside $700	Overweight Maintained	30 Apr 2025
BMO Capital Evan David Seigerman 28% 1-year accuracy 5 / 18 met price target	34% upside $800	Outperform Maintained	30 Apr 2025